» Articles » PMID: 23087764

Seroprevalence of Hepatitis B Surface Antigen and Anti Hepatitis C Antibody in Zahedan City, Iran: a Population-based Study

Overview
Journal Hepat Mon
Publisher Brieflands
Specialty Gastroenterology
Date 2012 Oct 23
PMID 23087764
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There have been studies regarding the prevalence of hepatitis B surface antigen (HBsAg) and anti-hepatitis C antibody (HCVAb) in Iran. However, the majority of these have reported a variety of rates, depending on their study population, which limits the generalizability of their results to the general population. On the other hand, cultural diversity in the different provinces of Iran also necessitates the performing separate population-based studies in the various regions.

Objectives: To evaluate the population-based prevalence of HBsAg and HCVAb and their correlates in Zahedan City, Iran.

Patients And Methods: Included in this study were 2587 individuals, using a random and cluster sampling approach. The participants were drawn from the Family Registry of the public health centers in Zahedan City, Iran, from 2008 to 2009. Following data collection from the interviews, subjects were assessed for seropositivity of HBsAg and HCVAb. We then calculated the prevalence of HBsAg and HCVAb, and evaluated these viral markers for an association with; age, sex and potential risk factors.

Results: Weighted seroprevalence of HBsAg and HCVAb was 2.5% (CI 95% : 1.9 to 3.3 %) and 0.5% (CI 95% : 0.27 to 0.9 %), respectively. Prevalence of HBsAg increased significantly with age (P value < 0.001), but this was not true for HCVAb (P value: 0.67). We observed no sex dominance in the prevalence of HBsAg (3.2% and 2.2% for males and females, respectively, P value: 0.15) or HCVAb (0.4% and 0.7% for males and females, respectively, P value: 0.27). In a multivariate regression analysis, every additional year in age resulted in a 2% increment in the odds of HBsAg seropositivity. HBsAg was also three times more prevalent among married, than single subjects (with a P value reaching toward significance: 0.065) in multivariate analysis. Prevalence of HCVAb did not differ with respect to any of the potential risk factors.

Conclusions: This is the first population-based study on the prevalence of HCVAb and one of the few population based studies on HBsAg in Zahedan City. We detected lower prevalence rates of HBsAg and HCVAb than in previous studies conducted in Zahedan City. In addition to improvements in social awareness and general health elements, we think that the observed low prevalence rates have been achieved due to the efficiency of mass vaccination projects, implemented against HBV infection in Iran.

Citing Articles

Seroepidemiological Investigation of Hepatitis B and C Prevalence and Associated Factors Among People in Custody at Zahedan Central Prison.

Metanat M, Almasi S, Sepehri Rad N, Tabatabaee S, Rezaei K Arch Iran Med. 2024; 27(6):298-304.

PMID: 38855799 PMC: 11264623. DOI: 10.34172/aim.23553.


Seroepidemiology and Risk Factors of Hepatitis B Virus Infection: A Population-Based Azar Cohort Study.

Pouri A, Ghojazadeh M, Shirmohammadi M, Eftekhar-Sadat A, Somi M Iran J Public Health. 2021; 49(11):2152-2160.

PMID: 33708736 PMC: 7917508. DOI: 10.18502/ijph.v49i11.4733.


The demographic and paraclinical characteristics of patients with hepatitis B presenting to Shahid Mohammadi Hospital and Clinic and other private clinics in Bandar Abbas, Iran.

Nazarnezhad M, Moosavy S, Davoodian P, Eftekhar E, Nejatizadeh A, Azad M J Adv Pharm Technol Res. 2019; 9(4):139-146.

PMID: 30637232 PMC: 6302689. DOI: 10.4103/japtr.JAPTR_328_18.


Lack of Association between Oral Lichen Planus and Hepatitis B and C Virus Infection - a Report from Southeast Iran.

Nosratzahi T, Raiesi M, Shahryari B Asian Pac J Cancer Prev. 2018; 19(6):1633-1637.

PMID: 29936791 PMC: 6103594. DOI: 10.22034/APJCP.2018.19.6.1633.


The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses.

Mahmud S, Akbarzadeh V, Abu-Raddad L Sci Rep. 2018; 8(1):150.

PMID: 29317673 PMC: 5760657. DOI: 10.1038/s41598-017-18296-9.


References
1.
Adibi P . Why we still need HBV population-based epidemiologic studies. Hepat Mon. 2012; 12(2):71-2. PMC: 3321323. DOI: 10.5812/hepatmon.842. View

2.
Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya M . Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy. 2007; 18(5):359-63. DOI: 10.1016/j.drugpo.2007.02.007. View

3.
Zali M, Mohammad K, Noorbala A, Noorimayer B, Shahraz S, Sahraz S . Rate of hepatitis B seropositivity following mass vaccination in the Islamic Republic of Iran. East Mediterr Health J. 2006; 11(1-2):62-7. View

4.
Alavian S, Fallahian F, Bagheri Lankarani K . The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2008; 16(4):403-6. View

5.
McMahon B . Natural history of chronic hepatitis B - clinical implications. Medscape J Med. 2008; 10(4):91. PMC: 2390714. View